Argos reports immunogenicity results of AGS-004 in HIV program
Argos announced immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response, defined as a greater than 2-fold increase from baseline. July 26, 2017